LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

LLY

916.07

-0.02%↓

UNH

566.13

-0.87%↓

NVO

118.17

+0.23%↑

JNJ

164.55

+0.16%↑

ABBV

188.57

-1%↓

Search

Bristol-Myers Squibb Co.

Closed

Sector Healthcare

53.4 1.5

Overview

Share price change

24h

Current

Min

52.76

Max

53.56

Key metrics

By Trading Economics

Income

14B

1.7B

Sales

300M

12B

P/E

Sector Avg

14.05

112.16

EPS

2.07

Profit margin

13.77

Employees

34,100

EBITDA

13B

4.4B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-4.97 downside

Dividends

By Dow Jones

Next Earnings

31 Oct 2024

Next Dividend date

1 Nov 2024

Next Ex Dividend date

2 Jan 2025

Market Stats

By TradingEconomics

Market Cap

-1.9B

107B

Previous open

51.9

Previous close

53.4

News Sentiment

By Acuity

23%

77%

54 / 366 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Bristol-Myers Squibb Co. Chart

Past performance is not a reliable indicator of future results.

Related News

30 Sept 2024, 13:06 UTC

Major Market Movers

Prime Medicine Shares Rally on Partnership With Bristol Myers Squibb

26 Jul 2024, 14:08 UTC

Earnings

Trending: Bristol Myers Squibb 2Q Adjusted EPS Beat Expectations

26 Jul 2024, 11:54 UTC

Earnings

Bristol-Myers 2Q Adjusted EPS Tops Views on Strong Sales

25 Apr 2024, 14:38 UTC

Earnings

Trending: Bristol Myers Squibb Cuts '24 EPS Outlook, Plans Job Cuts in Cost Saving Efforts

7 Oct 2024, 14:16 UTC

Earnings
Acquisitions, Mergers, Takeovers

Pfizer Stock Rises After It Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7 Oct 2024, 13:45 UTC

Earnings
Acquisitions, Mergers, Takeovers

Pfizer Stock Rises After It Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7 Oct 2024, 11:54 UTC

Top News

Pfizer Gets an Activist. What Starboard's Track Record With Pharma Tells Us. -- Barrons.com

7 Oct 2024, 09:30 UTC

Top News

Old Drug Repurposed for Schizophrenia Could Reap Alzheimer's Windfall -- Heard on the Street -- WSJ

27 Sept 2024, 18:36 UTC

Earnings

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, DJT, Wynn, HP Inc., Acadia Healthcare, and More -- Barrons.com

27 Sept 2024, 09:15 UTC

Hot Stocks

Stocks to Watch Friday: Bristol Myers Squibb, EchoStar, Costco -- WSJ

26 Sept 2024, 23:20 UTC

Top News

First Novel Schizophrenia Treatment in Decades Gains FDA Approval -- Update

26 Sept 2024, 22:56 UTC

Top News

First Novel Schizophrenia Treatment in Decades Gains FDA Approval -- WSJ

16 Aug 2024, 11:30 UTC

Top News

The Feds Are 'Playing Nice' With Pharma, at Least for Now -- Heard on the Street -- WSJ

8 Aug 2024, 10:30 UTC

Top News

Big Pharma Cuts R&D, Sending Shudders Through Industry -- Heard on the Street -- WSJ

29 Jul 2024, 10:30 UTC

Top News

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

26 Jul 2024, 14:51 UTC

Earnings

Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win -- IBD

26 Jul 2024, 13:53 UTC

Earnings

Trending: Bristol Myers Squibb 2Q Adj EPS Beat Expectations

26 Jul 2024, 11:28 UTC

Earnings

Bristol Myers Stock Jumps. A Sales Jump for Eliquis Boosts Earnings. -- Barrons.com

26 Jul 2024, 11:14 UTC

Earnings

Bristol Myers Squibb Earnings Easily Beat On Cost Cuts; Stock Jumps -- IBD

26 Jul 2024, 11:06 UTC

Earnings

Bristol-Myers Squibb 2Q Adj Gross Margin 75.6% >BMY

26 Jul 2024, 11:06 UTC

Earnings

Bristol-Myers Squibb 2Q Gross Margin 73.2% >BMY

26 Jul 2024, 11:04 UTC

Earnings

Bristol-Myers Squibb Raises 2024 View To EPS 60c-EPS 90c Vs Prior Guidance 40c-70c >BMY

26 Jul 2024, 11:04 UTC

Earnings

Bristol-Myers Squibb Now Sees 2024 Total Rev Up Upper End of Low Single-Digit Range >BMY

26 Jul 2024, 10:59 UTC

Earnings

Bristol-Myers Squibb 2Q EPS 83c >BMY

26 Jul 2024, 10:59 UTC

Earnings

Bristol-Myers Squibb 2Q Net $1.68B >BMY

26 Jul 2024, 10:59 UTC

Earnings

Bristol-Myers Squibb 2Q Rev $12.2B >BMY

26 Jul 2024, 10:59 UTC

Earnings

Bristol-Myers Squibb 2Q Adj EPS $2.07 >BMY

19 Jun 2024, 05:30 UTC

Top News
Acquisitions, Mergers, Takeovers

M&A Is Back. 4 Stocks That Could Be Targets. -- Barrons.com

28 May 2024, 22:51 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk

25 Apr 2024, 12:36 UTC

Earnings

Bristol Myers Cuts Full-Year Earnings Forecast, Launches Cost Cuts -- Barrons.com

Peer Comparison

Price change

Bristol-Myers Squibb Co. Forecast

Price Target

By TipRanks

-4.97% downside

12 Months Forecast

Average 50.72 USD  -4.97%

High 60 USD

Low 33.1 USD

Based on 17 Wall Street analysts offering 12 month price targets forBristol-Myers Squibb Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

17 ratings

3

Buy

11

Hold

3

Sell

Technical Score

By Trading Central

52.41 / 53.4057Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

54 / 366 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and fibrosis. Its pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Vidaza, Baraclude and Breyanzi. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics and government agencies.